Skip to main content
Premium Trial:

Request an Annual Quote

MDxHealth Signs Deals with MultiPlan, Three Rivers

NEW YORK (GenomeWeb News) – MDxHealth today said that it has signed agreements with MultiPlan and Three Rivers Provider Network to provide access to the firm's ConfirmMDx for Prostate Cancer test.

The Liege, Belgium-based molecular diagnostics firm said that the two providers combined cover 67 million lives in the US. MultiPlan, which is a healthcare cost management firm, contracts with 900,000 healthcare providers in the US and offers products to approximately 57 million consumers. Three Rivers is a preferred provider organization with more than 6000,000 providers in its network.

ConfirmMDx is an epigenetic-based test that helps clinicians differentiate patients with true negative biopsies from those at risk for occult cancer.

"These two agreements provide access to ConfirmMDx for 25 percent of the insured population within the US, further enabling market adoption of our test nationwide," MDxHealth CEO Jan Groen said in a statement.

Yesterday, MDxHealth announced that Bostwick Laboratories would offer the test through its urology network in the US.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.